|Assessment Status||Rapid Review Complete|
|Indication||Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA.|
|Rapid review commissioned||10/07/2023|
|Rapid review completed||20/07/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.